临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 54863-37-5

Dapansutrile

中文名称:3-(甲基磺酰基)丙腈
CAS号:54863-37-5
分子式: C4H7NO2S 分子量: 133.17
产品形式: Free Base
研发状态: Not yet recruiting
研发用途: Diabetes Mellitus Type 2
研究机构: University Hospital Basel Switzerland; European Union (Horizon Europe Programme); State Secretariat for Education Research and Innovation Switzerland; Olatec Therapeutics LLC
研发日期: May-24
研发阶段: Phase 2
Dapansutrile is a novel and selective NLRP3 inflammasome inhibitor.

CAS: 54-85-3

Isoniazid

中文名称:异烟肼
CAS号:54-85-3
分子式: C6H7N3O 分子量: 137.14
产品形式: free base
研发状态: Not yet recruiting
研发用途: Pediatric HIV Infection; Latent Tuberculosis
研究机构: Brigham and Women''s Hospital; APIN Public Health Initiatives; University of Cape Town
研发日期: May-24
研发阶段: Phase 1
Isoniazid is a prodrug that blocks the action of fatty acid synthase by interacting with KatG , used for the prevention and treatment of tuberculosis.

CAS: 548-04-9

Hypericin

中文名称:金丝桃素
CAS号:548-04-9
分子式: C30H16O8 分子量: 504.44
产品形式: free base
研发状态: Not yet recruiting
研发用途: NSCLC Stage IV
研究机构: Newsoara Biopharma Co. Ltd.
研发日期: December 1 2024
研发阶段: Phase 1
Hypericin (Hyp, HY) is a naturally occurring substance found in the common St. John's Wort (Hypericum species) with antidepressive, antineoplastic and antiviral (human immunodeficiency and hepatitis C virus) activities. Hypericin has inhibitory effects on MAO (monoaminoxidase), PKC (protein kinase C), dopamine-beta-hydroxylase, reverse transcriptase, telomerase and CYP (cytochrome P450).

CAS: 54-71-7

Pilocarpine HCl

中文名称:盐酸毛果芸香碱
CAS号:54-71-7
分子式: C11H16N2O2.HCl 分子量: 244.72
产品形式: Hydrochloride
研发状态: Not yet recruiting
研发用途: Xerostomia; Dry Mouth
研究机构: Maastricht University Medical Center; ZonMw: The Netherlands Organisation for Health Research and Development
研发日期: Jan-23
研发阶段: Phase 3
Pilocarpine HCl (NSC 5746) is a nonselective muscarinic acetylcholine receptor agonist used to produce an experimental model of epilepsy.

CAS: 54-62-6

Aminopterin

中文名称:氨基蝶呤
CAS号:54-62-6
分子式: C19H20N8O5 分子量: 440.41
产品形式: Free Base
研发状态: Completed
研发用途: Psoriasis
研究机构: Syntrix Biosystems Inc.; National Institute of Allergy and Infectious Diseases (NIAID)
研发日期: Jun-09
研发阶段: Phase 1
Aminopterin (4-amino Folic Acid, 4-amino PGA, 4-Aminofolic acid, 4-Aminopteroylglutamic acid, Aminopteroylglutamic acid, APGA, NSC 739), a folic acid antagonist, is a competitive inhibitor of dihydrofolate reductase (DHFR) with Ki of 3.7 pM.

CAS: 54573-75-0

Doxercalciferol

中文名称: 度骨化醇
CAS号:54573-75-0
分子式: C28H44O2 分子量: 412.65
产品形式: free base
研发状态: Completed
研发用途: Chronic Kidney Disease; Secondary Hyperparathyroidism; Chronic Renal Insufficiency; Chronic Renal Failure
研究机构: OPKO IP Holdings II Inc.; OPKO Health Inc.
研发日期: Nov-08
研发阶段: Phase 1
Doxercalciferol (1α-hydroxyvitamin D2) is a synthetic vitamin D2 analog, suppressing parathyroid synthesis and secretion, used to treat secondary hyperparathyroidism and metabolic bone disease.